New drug aims to reach brain tumors in recurrent glioblastoma
NCT ID NCT06883747
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a drug called BMS-986504 in up to 12 people with recurrent glioblastoma, a severe brain cancer. The drug targets tumors with a specific genetic change (MTAP loss). The study first checks if the drug can reach the brain tumor during surgery, then looks at safety and side effects. If the drug gets into the tumor well, participants may continue treatment to see if it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-986504 (MRTX1719), a targeted drug that blocks a protein called PRMT5, which helps certain cancer cells grow
What this could lead to
If it works, this could point toward a new treatment option for people with recurrent glioblastoma whose tumors have a specific genetic change (MTAP loss).
What could go wrong
This is a very early (Phase 0/1) and small trial (12 people). It mainly checks if the drug reaches the brain and is safe, not if it shrinks tumors. Many early drugs fail to show benefit in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA WHO GRADE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Joseph's Hospital and Medical Center
RECRUITINGPhoenix, Arizona, 85013, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••